Shanghai Labway Clinical Laboratory Co (301060) Fair Value & Analysis

Healthcare · CN · Market cap 3.4B CNY

Analysis

Shanghai Labway Clinical Laboratory Co (301060) currently trades at ¥8.65, while our model-based Fair Value estimate is ¥5.26 — implying the stock looks roughly 39.2% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing; and professional technical support services. In addition, the company offers rental, business, and human resources services. Further, it operates Lanwei Academy that provides open courses and internal training. The company serves medical and scientific research institutes. Shanghai Labway Clinical Laboratory Co., Ltd. was founded in 1993 and is headquartered in Shanghai, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.